Acquisition Announced
Gilead Sciences acquisition of Tubulis
US$3.1bn consideration
Announced 7 Apr 2026
Advisers
Tubulis
Target
- Financial adviser
- Legal adviser
- Goodwin

Team: Markus Käpplinger, Wei Xu, Sarah Solomon, Graham Defries, Kingsley L. Taft, Yifeng Yuan, Artimus Cunningham, Kyle Josias, Kenny Walker-Durrant, Robert Jochim, Bastian Schmack, Sarah Bock, James Devendorf, Dasol Lee, Jackie Klosek, Alison Liou, Jennifer Fay, Laura Horowitz, Daniel Karelitz, Shlomo Gottesman, Philipp Lauer, Arman Oruc, Stephen Mavroghenis, Danielle Fong, Hyunseok Doh, Elizabeth Mulkey, Jacob Osborn, Gozde Guckaya, Kuwabo Mubyana, Matt Wetzel
Gilead Sciences
Acquirer
- Financial adviser
- Legal adviser
- Target
- Tubulis
- Acquirer
- Gilead Sciences
- Seller
- EQT Life Sciences (LSP 7 fund)
- Target based in
- Germany
- Buyer based in
- United States
- Sector
- Biotech
- Tags
- Biotech, Oncology, Drug Development
In the league tables
Similar deals
- Eli Lilly and Company acquisition of Ajax Therapeutics Apr 2026 · US$2.3bn · Biotech
- Novartis acquisition of Pikavation Mar 2026 · US$2bn · Biotech
- Merck & Co. acquisition of Terns Pharmaceuticals Mar 2026 · US$6.7bn · Biotech
- GSK acquisition of Nuvalent Jun 2026 · US$11bn · Biotech
- Amgen acquisition of Dark Blue Therapeutics Jan 2026 · US$840m · Biotech
Sources
- 2026 Centerview Partners: Financial advisor to Gilead on its acquisition of Tubulis centerviewpartners.com
- 7 Apr 2026 Goodwin Advises Tubulis on Acquisition by Gilead for $3.15 Billion Upfront and Up to $1.85 Billion in Milestones goodwinlaw.com
- 7 Apr 2026 Press release (PR Newswire), EQT Life Sciences to exit minority stake in Tubulis via sale to Gilead Sciences for up to USD 5.0 billion prnewswire.com
- 8 Apr 2026 Goodwin Advises Tubulis on Sale to Gilead Sciences goodwinlaw.com



